Press release from Marketwire
Notice of 2012 Q1 Results Conference Call
Tuesday, May 08, 2012
TORONTO, ONTARIO--(Marketwire - May 8, 2012) - BioExx Specialty Proteins Ltd. ("BioExx" or the "Company") (TSX:BXI), announced today that it will release its financial results for the three month period ended March 31, 2012 following the close of markets on Monday, May 14, 2012. Management will host a conference call on Tuesday, May 15 at 9:00 a.m. (Eastern Time) to review the financial results.
|Live Conference Call:|
|Dial-in Numbers:||416-695-6616 / 800-355-4959 / 800-6578-9898|
|Dial-in Numbers:||905-694-9451 / 800-408-3053 / 800-3366-3052|
|Available Until:||May 29, 2012 11:59 PM|
The call will be audio-cast live and archived for 90 days at www.bioexx.com.
About BioExx Specialty Proteins Ltd.
Headquartered in Toronto, Canada, BioExx is focused on the separation of oil and high-value proteins from oilseeds for global food, beverage, nutrition, and other markets. BioExx employs trade secret, patented and patent-pending technologies that utilize significantly lower temperatures than conventional oilseed processing, in order to enable the improved separation of proteins from oilseeds. BioExx believes that these processes cumulatively have the potential to make a valuable contribution to global food and protein supply while maintaining an environmentally sustainable footprint.
To find out more about BioExx Specialty Proteins Ltd. (TSX:BXI), please visit www.bioexx.com.
The statements made in this press release include forward-looking statements that involve a number of risks and uncertainties. These statements relate to future events or future performance and reflect management's current expectations and assumptions. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements, such as the economy, generally, competition in its target markets, the demand for BioExx's products, the availability of funding, the efficacy of its technology, and the anticipated costs of BioExx's plant construction and operation. These forward-looking statements are made as of the date hereof and BioExx does not assume any obligation to update or revise them to reflect new events or circumstances. Actual events or results could differ materially from BioExx's expectations and projections.
FOR FURTHER INFORMATION PLEASE CONTACT:
Chris Schnarr BioExx Specialty Proteins Ltd. Chief Executive Officer (416) 588-4442 x111 firstname.lastname@example.org www.bioexx.com
Brisco Capital Partners Investor Relations: Scott Koyich President (403) 262-9888 email@example.com